首页> 外文OA文献 >Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-Î±-, NTRK1-) Non-Small Cell Lung Cancer Globally?

【2h】

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-Î±-, NTRK1-) Non-Small Cell Lung Cancer Globally?

机译：美国FDa要求同时共同开发伴随诊断（CDx）是否会延迟批准受体酪氨酸激酶抑制剂用于RTK重排（ROs1-，RET-，aXL-，pDGFR-α - ，NTRK1-）非 - 全球小细胞肺癌？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sai-Hong Ignatius Ou; Ross A. Soo; Akihito Kubo; Tomoya Kawaguchi; Myung-Ju Ahn;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Wen Gao, Jing He, Shi-Dai Jin, OncoTargets and therapy . 2019,第2期

机译：初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制作用的抗T790M突变抗性抗性抗性抗肺癌患者的抗性抗性，抗血疱剂血管生长因子受体酪氨酸激酶激酶抑制剂
2. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors [J] . Liu Yang, Wang Si, Dong Qian-Ze, Medical oncology . 2016,第3期

机译：非小细胞肺癌中P21激活的激酶表达模式不同，并且影响肺癌细胞对表皮生长因子受体酪氨酸激酶抑制剂的敏感性
3. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. [J] . Murray S, Dahabreh IJ, Linardou H, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第8期

机译：非小细胞肺癌中表皮生长因子受体的酪氨酸激酶结构域的体细胞突变和酪氨酸激酶抑制剂对TKI的反应。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1- RET- AXL- PDGFR-α- NTRK1-) Non-Small Cell Lung Cancer Globally? [O] . Sai-Hong Ignatius Ou, Ross A. Soo, Akihito Kubo, 2014

机译：美国FDA同时开发同伴诊断（CDx）的要求是否会延迟对RTK重排的（ROS1-RET-AXL-PDGFR-α-NTRK1-）非小型受体酪氨酸激酶抑制剂的批准全球细胞肺癌？
7. Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase (RTK) inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-a-, NTRK1-) non-small cell lung cancer globally? [O] . Sai-Hong Ignatius Ou 2014

机译：美国FDa同时共同开发伴随诊断（CDx）的要求是否会延迟批准RTK重排的受体酪氨酸激酶（RTK）抑制剂（ROs1-，RET-，aXL-，pDGFR-a-，NTRK1-）全球非小细胞肺癌？

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-Î±-, NTRK1-) Non-Small Cell Lung Cancer Globally?

著录项

相似文献

相关主题

期刊订阅